Amicus Therapeutics
   
contact us sitemap
 
 

Insider Stock Ownership

Name Relationship / Title Current Shares Trading Activity
barkas alexander e Director 2,213,474 View
barris peter j Beneficial Owner (10% or more) 851,183 View
bloch stephen m Director 0 View
canaan equity partners iii llc Beneficial Owner (10% or more) 2,050,790 View
chl medical partners ii side fund, l.p. Beneficial Owner (10% or more) 1,975,456 View
chl medical partners ii, l.p. Beneficial Owner (10% or more) 2,108,554 View
crowley john f Officer 26,900 View
dentzer james e Officer 35,375 View
fhm iv lp Beneficial Owner (10% or more) 920,664 View
garden state life sciences venture fund l p Beneficial Owner (10% or more) 1,064,822 View
kramlich c richard Beneficial Owner (10% or more) 851,183 View
licholai gregory p Officer 152 View
mount sinai school of medicine of new york university Beneficial Owner (10% or more) 365,599 View
neff p sherrill Director 1,419,762 View
new enterprise associates 11 lp Beneficial Owner (10% or more) 3,665,565 View
newhall charles w iii Beneficial Owner (10% or more) 851,183 View
palling david Officer 62,116 View
patterson matthew r Officer 58,549 View
perry mark w Beneficial Owner (10% or more) 851,183 View
prospect venture partners ii lp Beneficial Owner (10% or more) 2,213,474 View
quaker bio ventures lp Beneficial Owner (10% or more) 1,419,762 View
sblendorio, glenn Director 14,333 View
schaeffer orlov s nicole Officer 12,795 View
topper james n Director 920,664 View
weinhoff gregory m Director 2,108,555 View

Stock transaction information provided by EDGAR Online. Amicus Therapeutics makes no representation or warranty with respect any of to the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.